On 23 January 2026, the Court of Appeal delivered an important judgment in The Federal Republic of Nigeria v VR Global Partners LP & Ors, reaffirming the English courts' robust and pragmatic approach to case management in...more
The UK government has confirmed that it intends to bring forward legislation to reverse the effect of the Supreme Court’s 2023 decision in PACCAR and to clarify in statute that litigation funding agreements (LFAs) should not...more
The Bill is intended to restore the previous status quo in which litigation funding agreements were distinct from damages-based agreements and were not required to comply with additional special conditions....more
Effective October 1, 2023, certain aspects of reporting obligations under the Bayh-Dole Act changed, and further changes are potentially on the way. Frequent recipients of federal funding, such as universities and research...more
On July 13, 2022, the European Parliament and the European Council agreed on a new regulation concerning “foreign subsidiaries that distort the European market.” Their agreement is the final stage prior to voting on the...more
Pharmaceutical drug development is expensive. One recent study estimates that the median cost to develop a new drug is $985 million, while the average is $1.3 billion. And those figures appear to be on the low end of a broad...more
THE CHALLENGE: Around the world, we face a crisis in education. Situations ranging from wartime destruction to the COVID-19 pandemic interrupt children’s learning, which can lead to higher levels of illiteracy and economic...more
You won’t want to miss four days of exclusive, virtual events that bring together industry leaders, emerging standouts, innovators and investors from across the industry landscape at the largest healthcare investment...more